首页|分枝杆菌噬菌体的基础与应用进展

分枝杆菌噬菌体的基础与应用进展

扫码查看
由分枝杆菌引发的相关感染仍然是全球重大公共卫生问题,耐药性分枝杆菌的出现使其治疗愈发困难,寻找新的治疗方案迫在眉睫.在抗耐药菌方面,噬菌体的研究已经取得了显著进展.自然界中的噬菌体数量庞大,目前已有超过2 400株分枝杆菌噬菌体的基因组被测序,结果显示分枝杆菌噬菌体的基因组具有丰富的多样性和嵌合结构,其编码的抗结核活性多肽及蛋白质等物质在分枝杆菌感染引起的疾病诊断与治疗中具有巨大应用潜力.在实际应用中,噬菌体既可以直接治疗细菌感染,又可以作为基因编辑的递送工具.此外,噬菌体的特异性使其用于治疗时具有一定的安全性.综述了分枝杆菌噬菌体在疾病诊断、治疗和预防等方面的应用,展望了分枝杆菌噬菌体的应用前景,同时分析了其在基础应用研究中的优缺点.
Advances in the Basis and Application of Mycobacteriophages
Infectious diseases caused by mycobacteria have become a major public health problem worldwide.The emergence of drug-resistant mycobacteria is making prevention and control more difficult.There is an urgent need for new treatments.Some progress has been made in the study of bacteriophages in this regard.In nature,phages are abundant and capable of infecting bacterial microorganisms.To date,more than 2 400 whole genomes of mycobacteriophages have been sequenced,and the results show that the genome of mycobacterium phages has a rich diversity and mosaic structure.The peptides and proteins,encoded by the genome with anti-tuberculosis activity have great potential in the diagnosis and treatment of mycobacterial infections.In practical application,bacteriophage is not only used to directly treat infectious diseases,but also as an efficient tools for gene editing systems.The advantage of phage treatment is that the specific phage will not infect mammals and other bacteria in the body.Here,we review the potential application of mycobacteriophages in the diagnosis,treatment and prevention of mycobacterial infections,discuss the application prospects of mycobacteriophages,and analyze their advantages and disadvantages in basic application research.

MycobacteriophageAntibiotic resistanceRapid detectionTreatmentPhage vaccine

李春艳、戴宗贤、李炳娴、杨延辉

展开 >

宁夏医科大学基础医学院 宁夏回族自治区常见传染病防治重点实验室 银川 750004

宁夏医科大学总医院 宁夏临床病原微生物重点实验室 银川 750004

分枝杆菌噬菌体 耐药性 快速检测 治疗 噬菌体疫苗

宁夏回族自治区重点研发计划宁夏回族自治区教育厅高等学校科学研究

2021BEG03072NYG2024122

2024

中国生物工程杂志
中国科学院文献情报中心 中国生物技术发展中心 中国生物工程学会

中国生物工程杂志

CSTPCD北大核心
影响因子:0.589
ISSN:1671-8135
年,卷(期):2024.44(8)
  • 1
  • 14